Overview

IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IPI-145 after single and repeat oral administration, and to evaluate the effects of food and ketoconazole on the plasma pharmacokinetics of IPI-145.
Phase:
Phase 1
Details
Lead Sponsor:
Infinity Pharmaceuticals, Inc.
SecuraBio
Treatments:
Ketoconazole